Equities Analysts Issue Forecasts for CLDX FY2026 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Celldex Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will earn ($4.68) per share for the year. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%.

Several other research firms also recently commented on CLDX. The Goldman Sachs Group decreased their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Morgan Stanley cut their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Celldex Therapeutics in a research report on Friday. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. Finally, UBS Group cut their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics has an average rating of "Moderate Buy" and an average target price of $50.90.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX traded up $0.91 during mid-day trading on Tuesday, hitting $21.26. 2,775,996 shares of the stock were exchanged, compared to its average volume of 936,371. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -8.27 and a beta of 1.33. The firm's 50-day simple moving average is $19.43 and its 200 day simple moving average is $21.80.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics during the 4th quarter worth approximately $2,867,000. Values First Advisors Inc. lifted its stake in Celldex Therapeutics by 20.0% during the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 4,837 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Celldex Therapeutics by 52.9% in the 4th quarter. Handelsbanken Fonder AB now owns 21,100 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 7,300 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Celldex Therapeutics by 128.9% in the 4th quarter. Los Angeles Capital Management LLC now owns 15,421 shares of the biopharmaceutical company's stock valued at $390,000 after purchasing an additional 8,683 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Celldex Therapeutics by 20.9% in the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock valued at $11,435,000 after purchasing an additional 78,145 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.